<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780128</url>
  </required_header>
  <id_info>
    <org_study_id>14-011071</org_study_id>
    <nct_id>NCT02780128</nct_id>
  </id_info>
  <brief_title>Next Generation Personalized Neuroblastoma Therapy</brief_title>
  <acronym>NEPENTHE</acronym>
  <official_title>Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yael P Mosse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation Medicine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to match genomic aberrations in tumor cells at time of
      relapse to rationally designed combinations of molecularly targeted agents. This study will
      be done in two parts:

      Part I: Tumor will be accessed at study entry via a biopsy and subjected to deep sequencing
      to identify protocol-specified biomarkers for therapy assignment.

      Part II: If the tumor contains a genetic change defined by the study as being actionable, and
      other criteria are met, participants will be assigned to therapy based upon the genetic
      changes identified in the tumor biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities when combining ceritinib combined with ribociclib</measure>
    <time_frame>28-day cycle one of therapy</time_frame>
    <description>The primary variable is the incidence of dose limiting toxicities (DLTs) during the first 28 days of therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events of trametinib as characterized and graded by CTCAE V4.03</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events of single agent Trametinib in patients with RAS-driven relapsed/refractory neuroblastoma will be characterized and graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities of HDM201</measure>
    <time_frame>28-day cycle one of therapy</time_frame>
    <description>The primary variable is the incidence of dose-limiting toxicities (DLTs) during the first 28 days of therapy. Estimation of the maximum tolerated dose (MTD) of HDM201 will be based upon the estimation of the probability of DLT during the first 21 days of therapy for patients in the dose-escalation portion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from time zero to last quantifiable concentration</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, and 24 hours post first dose of cycle 1; pre-dose on day 8 of cycle 1</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady state</measure>
    <time_frame>pre-dose, 1, 2, 4, 6, and 24 hours on day 15 of cycle 1</time_frame>
    <description>The theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with overall objective response</measure>
    <time_frame>2 years</time_frame>
    <description>To describe whether the assigned targeted therapy can mediate anti-tumor effects in subjects with relapsed or refractory high-risk neuroblastoma within the context of a phase 1/phase1b biomarker-driven trial. Percentage of patients with objective response will be according to the International Neuroblastoma Response Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cataloguing of genomic alterations identified from biopsies performed at time of relapse in patients with relapsed or refractory neuroblastoma</measure>
    <time_frame>3 years</time_frame>
    <description>Neuroblastomas undergo substantial mutational evolution during therapy, and relapsed disease is more likely to be driven by a targetable oncogenic pathway. Genomic alterations measured by next-generation sequencing at time of disease progression will be characterized and reported in a descriptive manner.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Neuroblastoma</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.
Two different doses of ceritinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.
It is possible that if participants start at a lower dose of ribociclib, participants may take a higher dose once that dose has been deemed safe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified participants whose tumors show certain mutations in the rat sarcoma - mitogen activated protein kinase (RAS-MAPK) pathway (based on genetic sequencing results) will receive trametinib as a single agent, to be administered orally in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: p53</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified participants that do not match Groups 1 or 2, and whose tumors show wild-type p53 (based on genetic sequencing results) will receive HDM201 as a single agent, to be administered orally on Day 1 and Day 8 in 28-day cycles.
The investigators will perform a dose-escalation of HDM201. Once the investigators have identified the highest safe dose of HDM201, additional participants will be enrolled in the study at this dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Needle or incisional tumor biopsy</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <other_name>Genetic Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceritinib</intervention_name>
    <description>Participants will take ceritinib once per day orally for 28 days.</description>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <other_name>LDK378</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Participants will take trametinib once per day orally for 28 days.</description>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <other_name>MEKINIST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM201</intervention_name>
    <description>Participants will take HDM201 orally on Day 1 and Day 8 of a 28-day cycle.</description>
    <arm_group_label>Group 3: p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Next Generation Sequencing</intervention_name>
    <description>Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <other_name>Molecular Profiling</other_name>
    <other_name>Genetic Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor Scans</intervention_name>
    <description>Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1: ALK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>X-ray</intervention_name>
    <description>Participants will have x-rays of the wrist and leg.</description>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow Tests</intervention_name>
    <description>Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.</description>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3: p53</arm_group_label>
    <other_name>Bone marrow aspiration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical Exam</intervention_name>
    <description>The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3: p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eye Exam</intervention_name>
    <description>Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.</description>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <other_name>Ophthalmic Exam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Labs</intervention_name>
    <description>Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3: p53</arm_group_label>
    <other_name>Blood tests</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pregnancy Test</intervention_name>
    <description>If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3: p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Interviews</intervention_name>
    <description>A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.</description>
    <arm_group_label>Molecular Analysis</arm_group_label>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3: p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ECG</intervention_name>
    <description>This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.</description>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3: p53</arm_group_label>
    <other_name>EKG</other_name>
    <other_name>electrocardiogram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiogram</intervention_name>
    <description>The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.</description>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <arm_group_label>Group 2: RAS-MAPK</arm_group_label>
    <arm_group_label>Group 3: p53</arm_group_label>
    <other_name>echo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Participants will take ribociclib once per day orally for 21 days, followed by 7 days rest.</description>
    <arm_group_label>Group 1: ALK</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥1 years to ≤ 21 years

          -  Relapsed or refractory neuroblastoma

          -  A sufficient interval between the last dose of prior anti-cancer therapy (including
             cytotoxic and biological therapies) and enrollment in this study, to allow recovery
             from the acute toxic effects of all prior anti-cancer therapy. Please contact site for
             specific details

          -  Adequate bone marrow function (bone marrow may be involved with tumor. Contact site
             for specific details)

          -  Adequate renal function, defined as Creatinine clearance or radioisotope glomerular
             filtration rate (GFR) ≥ 70 mL/min/1.73 m2 OR serum creatinine based on age/gender
             normal (contact site for details)

          -  Adequate liver function, defined as total serum bilirubin ≤ 1.5 times the upper limit
             of normal AND alanine transaminase (ALT) ≤ 110 U/L.

          -  Adequate cardiac function, defined as corrected QT interval (QTc) ≤ 480 msec AND
             shortening fraction &gt; 27%

          -  Males and females who are sexually active must agree to use effective contraception
             during and for 3 months after treatment

        Exclusion Criteria:

          -  Subjects taking certain drugs or herbal medications that impact drug metabolism and/or
             cardiac function that cannot be discontinued (contact site for details).

          -  Subjects with concurrent severe and/or uncontrolled concurrent medical conditions that
             could compromise participation in the study (contact site for details)

          -  Other concomitant therapies:

          -  Corticosteroids initiated for tumor therapy within 7 days prior to study enrollment

          -  Other anti-cancer agents

          -  Other investigational drugs

          -  Hematological growth factors

          -  Radiation therapy

          -  Subjects &lt; 0.5m2

          -  Pregnant or lactating females

          -  Sexually active males unless they use a condom during intercourse while taking study
             drug/s and for 3 months after study drug discontinuation and thus do not attempt to
             father a child in this period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael P Mossé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia, The University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John M Maris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia, The University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alana Fitzsimmons, BS</last_name>
    <phone>2674252131</phone>
    <email>fitzsimmoa@email.chop.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alana Fitzsimmons, BS</last_name>
      <phone>267-425-2131</phone>
      <email>fitzsimmoa@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Yael P Mossé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John M Maris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rochelle Bagatell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, Pawel B, Cole KA, Maris JM. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. doi: 10.1158/1078-0432.CCR-13-1675. Epub 2013 Sep 17.</citation>
    <PMID>24045179</PMID>
  </reference>
  <reference>
    <citation>Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10.</citation>
    <PMID>25517749</PMID>
  </reference>
  <reference>
    <citation>Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, Christensen JG, Maris JM, Lemmon MA, Mossé YP. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011 Nov 9;3(108):108ra114. doi: 10.1126/scitranslmed.3002950.</citation>
    <PMID>22072639</PMID>
  </reference>
  <reference>
    <citation>Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NK, Boos J, Köhler G, Leuschner I, Pearson AD, Lunec J, Tweddle DA. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res. 2010 Feb 15;16(4):1108-18. doi: 10.1158/1078-0432.CCR-09-1865. Epub 2010 Feb 9.</citation>
    <PMID>20145180</PMID>
  </reference>
  <reference>
    <citation>Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017 May 15;23(10):2433-2441. doi: 10.1158/1078-0432.CCR-16-2898. Epub 2017 Apr 21.</citation>
    <PMID>28432176</PMID>
  </reference>
  <reference>
    <citation>Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clin Cancer Res. 2017 Apr 1;23(7):1785-1796. doi: 10.1158/1078-0432.CCR-16-1131. Epub 2016 Oct 11.</citation>
    <PMID>27729458</PMID>
  </reference>
  <reference>
    <citation>Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16;455(7215):930-5. doi: 10.1038/nature07261. Epub 2008 Aug 24.</citation>
    <PMID>18724359</PMID>
  </reference>
  <reference>
    <citation>Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.</citation>
    <PMID>23598171</PMID>
  </reference>
  <reference>
    <citation>Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017 Oct 1;35(28):3215-3221. doi: 10.1200/JCO.2017.73.4830. Epub 2017 Aug 8.</citation>
    <PMID>28787259</PMID>
  </reference>
  <reference>
    <citation>Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, Rubnitz KR, Sanford EM, Ali SM, Miller VA, Mossé YP, Granger MP, Weiss B, Maris JM, Modak S. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. PLoS Genet. 2016 Dec 20;12(12):e1006501. doi: 10.1371/journal.pgen.1006501. eCollection 2016 Dec.</citation>
    <PMID>27997549</PMID>
  </reference>
  <reference>
    <citation>Rihani A, Vandesompele J, Speleman F, Van Maerken T. Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma. Cancer Cell Int. 2015 Jul 30;15:76. doi: 10.1186/s12935-015-0224-y. eCollection 2015.</citation>
    <PMID>26225123</PMID>
  </reference>
  <reference>
    <citation>Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine JC, Westermann F, De Paepe A, Vandesompele J, Speleman F. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther. 2011 Jun;10(6):983-93. doi: 10.1158/1535-7163.MCT-10-1090. Epub 2011 Apr 1.</citation>
    <PMID>21460101</PMID>
  </reference>
  <reference>
    <citation>Van Maerken T, Vandesompele J, Rihani A, De Paepe A, Speleman F. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. Cell Death Differ. 2009 Dec;16(12):1563-72. doi: 10.1038/cdd.2009.138. Epub 2009 Sep 25. Review.</citation>
    <PMID>19779493</PMID>
  </reference>
  <reference>
    <citation>Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King FJ, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris JL, Mossé YP. Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. Clin Cancer Res. 2017 Jun 1;23(11):2856-2868. doi: 10.1158/1078-0432.CCR-16-1114. Epub 2016 Dec 16.</citation>
    <PMID>27986745</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Yael P Mosse</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>neuroblastoma</keyword>
  <keyword>cancer</keyword>
  <keyword>genetic profiling</keyword>
  <keyword>ceritinib</keyword>
  <keyword>ribociclib</keyword>
  <keyword>trametinib</keyword>
  <keyword>HDM201</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Ceritinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

